Dynamic changes of α-melanocyte-stimulating hormone levels in the serum of patients with craniocerebral trauma

The aim of the study was to investigate dynamic changes in a-melanocyte-stimulating hormone (alpha-MSH) levels in the serum of patients with craniocerebral trauma. Forty-eight patients with acute craniocerebral injury were selected between January 2015 and October 2016. The patients were divided into three groups: severe (18 cases), moderate (16 cases) and mild (14 cases), according to the Glasgow Coma Scale (GCS) score at the time of admission. At the same time, 10 adults with a similar age distribution to the patients were also selected as a control group. Venous blood was extracted from patients at 1, 3, 5 and 7 days after injury. Serum. a-MSH and tumor necrosis factor (TNF)-alpha levels were measured using an enzyme-linked immunosorbent assay (ELISA). The correlation between alpha-MSH and TNF-alpha was analyzed using Pearson's correlation analysis. Serum alpha-MSH levels in patients with craniocerebral injury were lower than those in the healthy control group (P < 0.05). Decreased serum alpha-MSH levels were usually accompanied with higher degrees of craniocerebral injury. Serum alpha-MSH levels initially decreased and then later increased, with the lowest alpha-MSH levels in the mild at 5 days, moderate at 5 days, and severe groups at 3 days after injury (P < 0.05). Serum TNF-alpha levels in all the patient groups were higher than those in the control group at different time points after injury, with higher TNF-alpha serum levels accompanying higher degrees of brain injury. In all three groups, serum TNF-alpha levels initially increased and then decreased post-injury, with peak serum TNF-alpha levels found at 3-day post injury in all the patient groups (P < 0.05). A negative correlation between serum a-MSH content and serum TNF-alpha levels in patients with craniocerebral trauma at different time points, was noted (P < 0.05). Serum alpha-MSH content in the survival group was higher than that in the death group (P < 0.05). Serum alpha-MSH levels in patients with non -systemic inflammatory response syndrome (SIRS) were higher than in patients with SIRS (P < 0.05). Serum alpha-MSH levels during the early stages after craniocerebral trauma can be used as a factor for the prediction of secondary SIRS, with constant low levels of serum alpha-MSH suggest poor prognosis.